⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3152130 | 1.00 | — | — | |
| SCHEMBL11685188 | 0.65 | — | — | |
| SCHEMBL1479353 | 0.65 | — | — | |
| SCHEMBL9530144 | 0.63 | — | — | |
| SCHEMBL11779706 | 0.60 | — | — | |
| SCHEMBL12837797 | 0.58 | — | — | |
| SCHEMBL30787924 | 0.58 | — | — | |
| SCHEMBL15314182 | 0.58 | — | — | |
| Bicarbonate SCHEMBL28129229 | 0.57 | — | — | |
| SCHEMBL13703812 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092731-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | ULTRAGENYX PHARMACEUTICAL INC. | 2024-03-21 | — | — | US | disclosed |
| US-11753369-B2 | Creatine prodrugs, compositions and methods of use thereof | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20220227703-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | ULTRAGENYX PHARMACEUTICAL INC. | 2022-07-21 | — | — | US | disclosed |
| US-11332438-B2 | Creatine prodrugs, compositions and methods of use thereof | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20210002211-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | ULTRAGENYX PHARMACEUTICAL INC. | 2021-01-07 | — | — | US | disclosed |
| EP-3717453-A2 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | Ultragenyx Pharmaceutical Inc. (US) | 2020-10-07 | — | — | EP | disclosed |
| US-8318935-B2 | Organic compounds 75074 | NOVARTIS AG (CH) | 2012-11-27 | — | — | US | disclosed |
| EP-2231280-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| US-20100105660-A1 | ORGANIC COMPOUNDS75074 | NOVARTIS AG (CH) | 2010-04-29 | — | — | US | disclosed |
| EP-2155721-A1 | ORGANIC COMPOUNDS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2009074575-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-06-18 | — | — | WO | disclosed |
| WO-2008135557-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-11-13 | — | — | WO | disclosed |
| US-5883132-A | MULTISTAGE REACTION OF AMIDATION, ACTIVATION, COUPLING AND HYDROLYSIS | FOURNIER INDUSTRIE ET SANTE (FR) | 1999-03-16 | — | — | US | disclosed |
| US-5733928-A | IMMUNOSUPPRESSANTS | FOURNIER INDUSTRIE ET SANTE (FR) | 1998-03-31 | — | — | US | disclosed |